ArticleFunctional & integrative genomics2024
Gene clusters-based pathway enrichment analysis identifies four pan-cancer subtypes with distinct molecular and clinical features.
Article in Functional & integrative genomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Pathways-based clustering methods have been proposed to explore tumor heterogeneity. However, such methods are currently disadvantageous in that specific pathways need to be explicitly claimed. We developed the PathClustNet algorithm, a pathway-based clustering method designed to identify cancer subtypes. This method first detects gene clusters and identifies overrepresented pathways associated with them. Based on the pathway enrichment scores, it reveals cancer subtypes by clustering analysis. We applied the method to TCGA pan-cancer data and identified four pan-cancer subtypes, termed C1, C2, C3 and C4. C1 exhibited high metabolic activity, favorable survival, and the lowest TP53 mutation rate. C2 had high immune, developmental, and stromal pathway activities, the lowest tumor purity, and intratumor heterogeneity. C3, which overexpressed cell cycle and DNA repair pathways, was the most genomically unstable and had the highest TP53 mutation rate. C4 overrepresented neuronal pathways, with the lowest response rate to chemotherapy, but the highest tumor purity and genomic stability. Furthermore, age showed positive correlations with most pathways but a negative correlation with neuronal pathways. Smoking, viral infections, and alcohol use were found to affect the activities of neuron, cell cycle, immune, stromal, developmental, and metabolic pathway in varying degrees. The PathClustNet algorithm unveils a novel classification of pan-cancer based on metabolic, immune, stromal, developmental, cell cycle, and neuronal pathways. These subtypes display different molecular and clinical features to warrant the investigation of precision oncology.
Indexed as
Identifiers
39607532What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.